Sarilumab (IL6R/CD126) - Research Grid Biosimilar

Sarilumab is a fully human anti-IL-6R monoclonal IgG1 antibody that binds to both membrane bound and soluble interleukin 6 (IL-6) receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6 1. Sarilumab was developped by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe Rheumatoid Arthritis (RA) in combination with methotrexate 4. RA is a chronic inflammatory disease characterized by polyarthritis and its treatment has been challenged by the different response in every patient 3. Subcutaneous administration of Sarilumab has been shown to decrease acute-phase reactant levels and improve in clinical RA symptoms 2.

Homo sapiens / IL6R/CD126 [Homo sapiens]

Unconjugated

Primary Antibodies, Biosimilars

CHO cells

Neuroscience

>95%

Batch dependent

PBS buffer pH7.5

None

Blue Ice

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

IgG1-kappa

Homo sapiens

REGN88, SAR153191